Speakers

Monday, April 12

S. Sethu K. Reddy, MD
Academia Collaborations with Industry – Lessons for the Future
4:00 – 4:45 PM
Professor of Medicine
Central Michigan University
Mount Pleasant, MI

Dr. Reddy is a Professor and Chair of Medicine. He has previously been Chief of Adult Diabetes at Joslin Diabetes Center, Harvard, in Boston and Chairman of Endocrinology, Diabetes & Metabolism at Cleveland Clinic and a VP for Medical Affairs at Merck. Dr. Reddy earned his medical degree in 1980 at the Memorial University of Newfoundland, Canada, and completed his fellowship in endocrinology and metabolism at the University of Toronto. His completed a research fellowship in cellular and molecular physiology at Harvard Medical School/Joslin Diabetes Center in Boston. In 1988, he returned to Canada to join the Faculties of Medicine and Biochemistry at Dalhousie University. He completed his MBA at Cleveland State University in 2002. Dr. Reddy’s research interests are primarily devoted to clinical endocrinology, including obesity and thyroid disorders, and the epidemiology of diabetes and its complications. He has authored and coauthored more than 150 articles, abstracts, and book chapters concerning these and related topics.


Michael R. Bishop, MD
Immune Cellular Therapy for Malignancy: TILS CAR T-Cells
4:45 – 5:05 PM
Director, Hematopoietic Cellular Therapy Program
University of Chicago
Chicago, IL

Michael R. Bishop, MD, specializes in the diagnosis and treatment of lymphomas and leukemias. In particular, he cares for patients with hematologic malignancies that have not responded to first-line treatments. An expert in hematopoietic stem cell transplantation (bone marrow transplantation) and cellular therapy, Dr. Bishop and his team are working to address the unique social, economic, physiological and biological issues that patients face while undergoing this treatment. Dr. Bishop's research focuses on the prevention and treatment of relapse after stem cell transplantation. Relapse is the primary cause of treatment failure and death after stem cell transplantation. He has served as the primary investigator on studies designed to prevent and treat disease recurrence after transplantation. Specifically, he works on ways to enhance immune effects of the transplanted cells against cancer. An active contributor to medical literature, Dr. Bishop has authored more than 150 peer-reviewed articles, in addition to more than 30 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including Biology of Blood and Marrow Transplantation. Dr. Bishop is a dedicated mentor, teaching residents and fellows in classroom, clinical and research settings. Many of his past trainees hold leadership roles in medical oncology and immunology at academic medical centers or at the National Cancer Institute in Bethesda, Maryland. Since 2001, Dr. Bishop has consistently been named one of the "Best Doctors in America" by Best Doctors, Inc. He previously served as a senior investigator and as the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.


Stella M. Davies, MBBS, PhD
Why does Thrombotic Microangiopathy Occur after Stem Cell Transplant?
5:05 – 5:25 PM
Professor and Division Director
Cincinnati Children's Hospital Medical Center

As director of the Division of Bone Marrow Transplantation and Immune Deficiency at the Cincinnati Children’s Hospital, Dr. Davies has helped pioneer significant advances in bone marrow transplantation to improve survival rates and reduce toxicity. She has led efforts to sustain and improve an already-strong clinical center of excellence for the care of Fanconi patients and their families. She has also played a key role at Cincinnati in fostering and supporting strong clinical and basic science focused on Fanconi anemia. She is an active and vocal participant in the FA scientific community and brings her intellect, energy, and enthusiasm to the fight against Fanconi anemia.


Shernan Holtan, MD
Lessons from the Biology of Pregnancy Applied to Graft-Versus-Host Disease
5:25 - 5:45 PM
Associate Professor of Medicine

University of Minnesota

Dr. Holtan is Associate Professor of Medicine in the Division of Hematology, Oncology, and Transplantation, where she serves as a hematologist focusing on allogeneic hematopoietic cell transplantation for malignant and non-malignant diseases, GVHD, and long-term survivorship. She also serves as a clinical/translational investigator focused on personalized immune monitoring, inflammation resolution through strength training, and the role of wound healing-associated growth factors in graft-versus-host disease. Dr. Holtan brings a strong track record of multidisciplinary research to the University of Minnesota, studying the parallels of pregnancy and transplantation medicine in collaboration with physicians and scientists in obstetrics, maternal fetal medicine, immunology, and bioinformatics.


Armand Krikorian, MD
Scientists on Social Media: Claiming the Digital Space
6:35 - 7:05 PM
Vice-Chair and Residency Program Director

University of Illinois at Chicago / Advocate Christ Medical Center

Dr. Krikorian is the Vice-Chair and Residency Program Director of the Department of Internal Medicine at Advocate Christ Medical Center and Associate Professor of Clinical Medicine at the University of Illinois at Chicago. Prior to his tenure, he served as Associate Program Director for Internal Medicine at Case Medical Center in Cleveland, Ohio and Assistant Professor of Endocrinology at Case Western Reserve University. He also was the Associate Medical Director for the UH Accountable Care Organization. Dr. Krikorian received his Medical Degree from the American University of Beirut and completed his residency training and fellowship in Diabetes, Endocrinology and Metabolism at Case Western Reserve University. He currently serves on the Board of Directors of the American Association of Clinical Endocrinologists and on the program planning committee of the Association of Program Directors of Internal Medicine. He is also the past-president of the American Federation of Medical Research. Dr. Krikorian was a co-investigator in the ACCORD study and is published widely in several peer-reviewed journals. He has been recognized by multiple awards locally and nationally and has presented his work on graduate medical education, patient safety and diabetes at numerous national and international conferences.


Tuesday, April 13

Mary Beth Humphrey, MD, PhD
Department Chair Session: University of Oklahoma Health Sciences Center
4:00 – 4:30 PM
Associate Dean of Research
Professor of Medicine
McEldowney Chair in Immunology
Division Chief of Rheumatology, Immunology and Allergy

Dr. Humphrey grew up in Dallas, TX and completed her B.A. in Biology, magnum cum laude, at Austin College. She completed her MD, PhD in the Medical Science Training Program (MSTP) at Baylor College of Medicine. Dr. Humphrey subsequently completed Internal Medicine internship, residency, and Chief residency as well as Rheumatology fellowship at the University of California San Francisco. In 2007, she was recruited to the University of Oklahoma Health Sciences Center in the Department of Medicine, Division of Rheumatology. She was promoted to Associate professor with Tenure in 2012 and Professor in 2015. Beginning in 2013, she serves as the Division Chief of Rheumatology at OUHSC and in 2019 became the Associate Dean for Research for the College of Medicine. Dr. Humphrey was named the James R. McEldowney Chair in Immunology in 2009 and received the She has maintained research funding on myeloid cell contributions to osteoporosis, bone remodeling, and dementia since 2003. As a board-certified Rheumatolgy clinician, she proudly serves at the Oklahoma City Veterans Affairs Medical Center and at the OU Medical Center.


Parthasarathy Chandrakesan, PhD
Targeting KRAS Mutated Lung Cancer
Assistant Professor of Research
University of Oklahoma Health Sciences Center

Parthasarathy Chandrakesan, Ph.D., Assistant Professor, Dept. of Medicine, OUHSC Dr. Chandrakesan is an Assistant Professor in the Department of Medicine, Oklahoma University Health Sciences Center, USA. He has a broad background in pancreatic cancer, immune-oncology, cancer stem cell, and molecular targeting, and preclinical models relevant to the background knowledge. Dr. Chandrakesan completed his PhD. in the Department of Endocrinology, IBMS, India, where he investigated the role of adrenal hormones in immune regulation and male reproduction. Dr. Chandrakesan conducted his post-doctoral research in the Division of Digestive Diseases and Nutrition, OUHSC, where he developed a novel 3D organoid system to study inflammation on immune regulation and stem cell transdifferentiation into a cancer phenotype. In 2013, he joined the faculty at the Department of Medicine, OUHSC, conducting research on DCLK1 protein kinase and DNA damage response and macrophage polarization. Dr. Chandrkasan expanded his research to investigate the functional role of Dclk1 and Dclk1+ cells in cancer initiation, and metastasis and drug resistance in relevance to immune evasion. Primary focus is on pancreatic tumor immunosuppressive microenvironment and anti-tumor immunity. His current research goal is to strengthen and enhance the host anti-tumor immunity against various solid tumor cancers and to develop immune therapies and combinatorial therapies for the effective treatment of cancers with immunosuppressive phenotype.


Matlock A. Jeffries, MD
Studies of the Microbiome in Osteoarthritis
Assistant Professor of Medicine, Rheumatology
University of Oklahoma Health Sciences Center

Dr. Matlock Jeffries received his MD degree in 2010 from the University of Oklahoma, and subsequently completed his Residency in Internal Medicine in 2013 with a subsequent year as a peer-selected Chief Resident in 2014. He went on to finish Fellowship training in Rheumatology in 2016 and then joined faculty at the University of Oklahoma and the Oklahoma Medical Research Foundation. He is dual board certified in Internal Medicine and Rheumatology, and his clinical work focuses on the early recognition and treatment both osteoarthritis and rheumatoid arthritis. He has pursued basic science and translational research extensively since 2005; his research mentors have included Dr. Amr Sawalha MD, autoimmunity epigenetics specialist and Dr. Judith James MD PhD, autoimmunity and genetics expert. His research focuses on the contributions of epigenetics and the microbiome to rheumatic disease, particularly studying epigenetic patterns that may underlie the development and progression of osteoarthritis (OA), the most common age-related musculoskeletal disease worldwide. In 2014, he published one of the first genome-wide DNA methylation studies of OA cartilage, and subsequently published the first study of OA subchondral bone epigenetics and peripheral blood epigenetic patterns as OA biomarkers. His laboratory combines a large range of molecular techniques to examine both epigenetic changes in a diverse set of tissues as well as the transcriptional and functional consequences of these changes. His laboratory has recently begun examining the influence of the gut and cartilage microbiomes in OA, having demonstrated for the first time the presence of microbial DNA in human and mouse cartilage.


Matthew S. Walters, PhD
NOTCH3 Regulation of Human Airway Epithelial Club Cell Differentiation
Assistant Professor of Medicine
University of Oklahoma Health Sciences Center

The major focus of my research program is to understand the cellular processes that regulate airway epithelial stem/progenitor cell fate decisions during repair and regeneration of the lung. Alterations in the normal ratio of differentiated epithelial cell types (defined as epithelial remodeling) are associated with multiple chronic lung diseases including asthma, cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The overarching goal of my research is to identify signaling pathways that regulate differentiation of airway epithelial stem/progenitor cells into specific cell types thus providing novel targets for developing new therapies to treat chronic lung disease.


Michael Lauer, MD
Effect of COVID-19 in the Research Workplace
Panel Discussion
4:30 - 5:30 PM
Deputy Director for Extramural Research
National Institutes of Health


Michael Lauer, MD is the Deputy Director for Extramural Research at the National Institutes of Health (NIH), where he serves as the principal scientific leader and advisor to the Director of the NIH on all matters relating to the substance, quality, and effectiveness of the NIH extramural research program and administration. He received education and training at Rensselaer Polytechnic Institute, Albany Medical College, Harvard Medical School, Harvard School of Public Health, and the NHLBI’s Framingham Heart Study. He spent 14 years at Cleveland Clinic as Professor of Medicine, Epidemiology, and Biostatistics. During his tenure at the Clinic, he led a federally funded internationally renowned clinical epidemiology program that applied big data from large-scale electronic health platforms to questions regarding the diagnosis and management of cardiovascular disease. From 2007 to 2015 he served as a Division Director at the National Heart, Lung, and Blood Institute (NHLBI), where promoted efforts to leverage big data infrastructure to enable high-efficiency population and clinical research and efforts to adopt a research funding culture that reflected data-driven policy. He has received numerous awards including the NIH Equal Employment Opportunity Award of the Year and the Arthur S. Flemming Award for Exceptional Federal Service in recognition of his efforts to grow a culture of learning and accountability.


Joan D. Beckman, MD, PhD
Effect of COVID-19 in the Research Workplace
Panel Discussion
4:30 – 5:30 PM
Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota


I am a dedicated physician-scientist who is passionate about caring for patients with benign hematologic conditions. I have a clinical interest in patients with acquired and congenital bleeding disorders as well as patients with anemia. I conduct translational research in the molecular and cellular mechanisms driving inflammation-induced pathology in endothelial cells and blood vessels My current research focuses on evaluating the contribution of red blood cell and endothelial cell interactions in JAK2 V617F and CALR+ myeloproliferative neoplasm patients.


Kristin Sainani, PhD
Writing in the Sciences
6:20 – 6:55 PM
Associate Professor
Stanford University

Kristin Sainani (née Cobb) is an associate professor at Stanford University. She teaches statistics and writing; works on statistical projects in sports medicine; and writes about health, science, and statistics for a range of audiences. She authored the health column Body News for Allure magazine for a decade. She is also the statistical editor for the journal Physical Medicine & Rehabilitation; and she authors a statistics column, Statistically Speaking, for this journal. She was the recipient of the 2018 Biosciences Award for Excellence in Graduate Teaching at Stanford University. She offers an online medical statistics certificate program through the Stanford Center for Professional Development and teaches the popular Massive Open Online Course (MOOC) Writing in the Sciences on Coursera.

 


Wednesday, April 14

James Lawler, MD, MPH, FIDSA
Challenges of Conducting Research on Rare Viral Illness such as Ebola
4:00 – 4:45 PM
Executive Director for International Programs and Innovation
Global Center for Health Security
Associate Professor, Infectious Disease Division
Department of Internal Medicine
University of Nebraska Medical Center

Dr. James Lawler is an executive co-director for the Global Center for Health Security and Deputy Medical Director of the Nebraska Biocontainment Unit. Before joining the UNMC team in November 2017, he served 21 years in the US Navy Medical Corps. Dr. Lawler is an infectious disease physician trained in tropical medicine and public health whose career has focused on research and policy related to emerging infectious diseases, pandemic threats, and health system and public health preparedness.

Dr. Lawler previously served on the White House staff in both the Homeland Security Council Biodefense Office and the National Security Council Resilience Directorate, where he led development and coordination of national policy related to medical and public health preparedness, pandemic and public health emergency response, medical countermeasure R&D, biosurveillance, and clinical care for domestic and international health threats. Other career assignments included Principal Investigator at the US Army Medical Research Institute for Infectious Diseases (USAMRIID), Chief Medical Officer for the National Institute for Allergy and Infectious Diseases (NIAID) Integrated Research Facility at Fort Detrick, and Deputy Director of the US Central Command’s Joint Combat Casualty Research Team, overseeing all Department of Defense (DoD) medical research in the Afghanistan theater of operations. Dr. Lawler spent his last five years on active duty at the Naval Medical Research Center founding and developing the Austere environment Consortium for Enhanced Sepsis Outcomes (ACESO), an international research collaboration that is focused on improving sepsis survival in resource-limited settings. ACESO continues to conduct high-impact research in 6 countries across 4 continents.

Dr. Lawler is a subject matter expert in infectious disease outbreak response and research, with field experience in multiple viral hemorrhagic fever outbreaks in sub-Saharan Africa. In May of 2014, Dr. Lawler deployed to Conakry, Guinea as a World Health Organization (WHO) clinical consultant, working alongside Medecins Sans Frontieres and an international team to improve clinical care in Ebola treatment units. He assisted the DoD Joint Staff force health protection planning process for West Africa Ebola response (Operation United Assistance), briefing the Chairman, Joint Chiefs, and senior Pentagon officials. In October 2014, Dr. Lawler was the lead trainer standing up the DoD Northern Command’s Ebola Medical Support Team, created in response to a direct White House tasking for DoD support of US hospitals, and served as the team’s principal technical expert. Additional operational and field medical experience include duty as a Marine infantry battalion surgeon, in disaster relief operations aboard the hospital ship USNS Comfort, and with the NATO Role 3 Hospital in Kandahar, Afghanistan.

In response to the COVID-19 pandemic, Dr. Lawler made a number of early contributions in research, training, and clinical operations. He assisted in leading a small team that deployed to Yokohama, Japan to repatriate American citizens quarantined aboard the cruise ship Diamond Princess, coordinated quarantine and isolation care for some of the first cohorts of exposed/infected Americans returned from Wuhan and Yokohama, participated in site-initiation of the first hospital to conduct a randomized-controlled trial of remdesivir for COVID-19, and characterized environmental contamination related to care of COVID-19 patients. Dr. Lawler advised local, state, and national leadership on COVID-19 response as well a variety of entities in the public and private sector.

Dr. Lawler is board certified in internal medicine and infectious diseases and is a diplomate in tropical medicine and travelers’ health. He completed his fellowship in infectious diseases at the combined National Naval Medical Center (NNMC)/Walter Reed Army Medical Center program and his internship and residency in internal medicine at NNMC in Bethesda, MD. He received a Master of Public Health degree from the Uniformed Services University of the Health Sciences. Dr. Lawler graduated from Georgetown University School of Medicine after receiving his undergraduate degree in biomedical engineering from Duke University.


Sanjeev Akkina, MD
Does the Microbiome Predict Kidney Disease or does it Influence it?
4:45 – 5:00 PM
Associate Professor of Medicine
Loyola University Medical Center


Sanjeev Akkina, MD, is an Associate Professor of Medicine in the Division of Transplant Nephrology at Loyola University Medical Center in Maywood, IL.  Dr. Akkina’s research interests include non-invasive biomarkers of kidney allograft dysfunction and urinary microbiome changes associated with transplantation.  He is the principal investigator to multiple industry sponsored investigations including a phase 3 clinical trial in cellular immunotherapy for inducing functional immune tolerance in living donor kidney transplant recipients and for multiple cell-free DNA studies in kidney and multi-organ transplantation.  Dr. Akkina is also a co-investigator in a prospective observational study examining changes to the urinary microbiome in living donor kidney transplant recipients.   


Bruce Kaplan, MD
Transplant Biomarker Development
5:00 – 5:45 PM
Visiting Professor, Medicine-Renal Med Diseases/Hypertension
University of Colorado Anschutz Medical Campus

Bruce Kaplan, MD was Vice President at Baylor Scott and White before starting at the University of Colorado Anschutz Medical Campus. Before coming to Baylor Scott and White, Dr. Kaplan held the Kathy and Harry Jentsch Chair at the University of Arizona. Prior to that, Dr. Kaplan was awarded the highest achievement at the University of Florida and given the rare honor of Eminent Scholar in kidney research for his work on pharmacology and immunology as it relates to kidney failure. He was also awarded the Harvard University Visiting Lectureship in 2005. Dr. Kaplan received his Medical Degree from the College of Physicians and Surgeons at Columbia University in New York, New York. Dr. Kaplan’s research interests include kidney transplantation, complex systems and immune pharmacology, he is internationally recognized in immunosuppressive pharmacology and outcomes in transplantation. Dr. Kaplan has published more than 300 peer-reviewed papers (some of the most cited in the field), 30 book chapters and is author of a new textbook on Immunopharmacology. His articles have been published in various journals, including American Journal of Transplantation, Transplantation, Nature, Clinical Pharmacology and Therapeutics and Journal of Clinical Investigation. Dr. Kaplan was Deputy Editor for American Journal of Transplantation and is now Executive Editor of Transplantation. He has mentored numerous fellows and faculty. Three of his fellows were winners of young investigator awards by the major transplant society. Six of his trainees are now Medical Directors of renal transplant at major programs.


Jay Koyner, MD
Biomarkers of Acute Kidney Injury
5:45 &ndash 6:00 PM
Professor of Medicine
University of Chicago


Jay L. Koyner, MD, is a Professor of Medicine in the Section of Nephrology at the University of Chicago. Dr. Koyner’s critical care nephrology research interests have focused on the utilization of plasma and urine biomarkers to improve patient risk stratification and outcomes in the setting of AKI. He has contributed to several multi-center studies investigating the biomarkers of AKI, including the TRIBE-AKI study, the Furosemide Stress Test study and several industry sponsored investigations. More recently he has begun developing and implementing an electronic health record derived AKI risk score, with the hopes of improving the care of patients at high risk for the development of severe hospital acquired AKI. He has published over 110 peer-reviewed articles and book chapters on AKI and the care of patients with kidney injury in the ICU and is the Editor of the forthcoming " Handbook of Critical Care Nephrology."


Thursday, April 15

Shawn C. Burgess, PhD
Mapping Mitochondrial Nutrient Metabolism in Liver
4:00 – 4:45 PM
Associate Professor
UT Southwestern Medical Center


Shawn C. Burgess obtained his PhD in Chemistry in 2000 from the University of Texas at Dallas for research on using carbon-13 tracers and nuclear magnetic resonance (NMR) to examine metabolic flux. From 2000-2003 he was a postdoctoral research scientist in the Department of Radiology at UT Southwestern where he studied substrate metabolism in β-cell and liver using tracer approaches. In the Center for Human Nutrition, the Burgess Lab uses stable isotope tracers, NMR and mass spectrometry to study how metabolic flux is regulated by molecular physiology and altered by disease or pharmacology. His lab focuses on pathways of oxidative and biosynthetic metabolism in the context of obesity, insulin resistance and diabetes. They seek to understand how metabolic mechanisms contribute to pathologies of disease such as steatosis, oxidative stress and inflammation.


Yuwei Jiang, PhD
Modulating Thermogenic Beige Fat for Metabolic Health
4:45 – 5:00 PM
Assistant Professor
University of Illinois at Chicago


Dr. Jiang is originally from China and received her B.S degree in Biological Sciences from Fudan University, China. She was awarded her Ph.D degree in Molecular and Human Genetics from Baylor College of Medicine where she focused on organ development, disease modeling and gene regulations. She then moved to the University of Texas Southwestern Medical Center as a Postdoctoral Fellow in the Department of Developmental Biology and the Division of Endocrinology. Dr. Jiang started as an assistant professor in the Department of Physiology and Biophysics in August 2018. Her current research focuses on the roles of adipose stem cells in adipose tissue development, expansion, and aging. The induction of thermogenic beige adipocytes in white adipose tissue is a promising avenue for the treatment of obesity and Type 2 diabetes. In this seminar, she will discuss new mechanisms regulating beige adipocyte formation and maintenance that could be developed therapeutically.


Matthew J. Potthoff, PhD
Endocrine Regulation of Carbohydrate Homeostasis by FGF21
5:00 – 5:15 PM
Roy J. Carver Associate Professor in Neuroscience and Pharmacology
F.O.E. Diabetes Research Center and Iowa Neuroscience Institute
Director, Molecular Medicine Graduate Program
Carver College of Medicine


Matthew J. Potthoff grew up in Oklahoma and graduated Summa Cum Laude from the University of Oklahoma in 2003. He then obtained his Ph.D. in 2007 from the University of Texas Southwestern Medical Center and then performed a Howard Hughes Postdoctoral Fellowship where he examined the role of endocrine fibroblast growth factors in regulating hepatic metabolism.  In 2012, Dr. Potthoff moved to the University of Iowa and joined the Department of Pharmacology and the F.O.E. Diabetes Research Center.  His primary research interests are on the role of liver-derived factors, termed hepatokines, in regulating systemic energy homeostasis.
 


Friday, April 16

Scott E. Parazynski, MD
Innovation in the Extreme
4:00 – 4:45 PM
Physician and Former NASA Astronaut 

Dr. Scott Parazynski is a highly decorated physician, astronaut, and tech CEO, recently inducted into the US Astronaut Hall of Fame. He is a widely sought after keynote speaker on innovation, risk management, mentorship and leadership under extreme adversity. Scott has lived and traveled all over the world, spending many of his grade school years in places such as Senegal, Lebanon, Iran and Greece.

A graduate of Stanford University and Medical School, he went on to train at Harvard and in Denver for a career in emergency medicine and trauma. In 1992 he was selected to join NASA’s Astronaut Corps and eventually flew 5 Space Shuttle missions and conducted 7 spacewalks. Mission highlights include a global ozone mapping flight; leading the first joint US-Russian spacewalk while docked to the Russian space station Mir; serving as Senator John Glenn’s crewmate and “personal physician”; and assembly of the Canadian-built space station robotic arm.

In October 2007, Scott led the spacewalking team on STS-120, during which he performed 4 EVAs. The final EVA is regarded by many as one of the most challenging and dangerous ever performed. The tremendous coordinated effort in orbit and on the ground by Mission Control has been likened to the Space Shuttle and Space Station era’s “Apollo 13 moment.” In addition to being a diver and accomplished mountaineer, Scott is also a commercial, instrument, multiengine and seaplane-rated pilot. On May 20, 2009, he became the first astronaut to stand on top of the world, the summit of Mount Everest.

As a life-long explorer, he and a colleague recently set the first bootprints adjacent the world’s youngest lava lake, inside the crater of Massaya Volcano in Nicaragua. He is a prolific inventor/product developer, and serves on the Boards of several companies. He is Founder and CEO of Fluidity Technologies, focused on the development of revolutionary input devices powered by machine learning to intuitively move through physical and virtual space.


Nizar N. Jarjour, MD
Aspects of the Extrapulmonary Effects of Asthma and Cardiovascular Effects
4:45 – 5:30 PM
Professor of Medicine
University of Wisconsin School of Medicine

Dr. Nizar N. Jarjour is a Professor of Medicine, and Head, Division of Allergy, Pulmonary & Critical Care Medicine in the Department of Medicine. He also serves as director of the Clinical and Translational Research Core at the University of Wisconsin Institute for Clinical and Translational Research, Madison, WI. Dr. Jarjour's research program include mechanisms of allergic inflammation, role of eosinophil in airway disease, pathogenesis of viral induced asthma exacerbations, etiology and characteristics of severe asthma, mechanisms of action of anti-asthma medication, airway remodeling and clinical aspects of asthma.

He is Board Certified in Internal Medicine, Pulmonary and Critical Care Medicine. His clinical activities include staffing the University of Wisconsin Hospital Trauma and Life Center, outpatient and inpatient pulmonary consultations and directing the Pulmonary Diagnostics Laboratory.

Dr. Jarjour is an instructor on three research training awards in Allergy-Immunology, Neurobiology and Cellular & Molecular Pathology. He is a past president of the Wisconsin Thoracic Society and a current member of the Respiratory Integrated Biology Study Section at National Institute of Health. Dr. Jarjour is a member of the American Thoracic Society, American College of Physicians and American College of Chest Physicians.


Paul Reyfman, MD, MS
Single Cell Analysis of Lung Populations in Pulmonary Fibrosis
5:30 – 5:50 PM
Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine

I am a physician scientist in the Division of Pulmonary and Critical Care Medicine. I received an MD and then completed residency in internal medicine at the Columbia University College of Physicians and Surgeons. I came to Northwestern for fellowship training in pulmonary and critical care medicine, and then joined the faculty here in 2017. My research focus is in applying systems biology approaches to studying respiratory health, the effects of aging on the lung, and chronic lung diseases including pulmonary fibrosis and chronic obstructive pulmonary disease. My clinical focus is in pulmonary medicine, particularly in obstructive lung diseases including chronic obstructive pulmonary disease (COPD) and asthma.